NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS

用于恒河猴 HIV/SIV 的新型重组腺病毒疫苗载体

• 批准号: 7715455
• 负责人: Dan H. Barouch
• 金额: $ 23.79万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-05 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7715455
• 关键词: Adenoviruses; Antigens; Computer Retrieval of Information on Scientific Projects Database; Development; Frequencies; Funding; Grant; HIV-1; HIV-1 vaccine; Human; Immune response; Immune system; Immunity; Institution; Macaca mulatta; Recombinants; Research; Research Personnel; Resources; Safety; Serotyping; Source; United States National Institutes of Health; Virus; immunogenicity; novel; novel vaccines; vector; vector vaccine; vector-based vaccine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A critical roadblock in the development of an HIV-1 vaccine is our current inability to deliver HIV-1 antigens efficiently to the immune system and to prime predictable, high frequency immune responses in humans. It is also important to develop vaccine vectors that are not subject to pre-existing anti-vector immunity. For example, the high frequency of pre-existing immunity to the Ad5 vector has been shown to suppress the immunogenicity and possibly impair the safety of rAd5 vaccines for HIV-1. To overcome this hurdle, we have developed novel replication-incompetent rAd vector-based vaccines derived from rare Ad serotypes and chimeric viruses, and we are assessing the immunogenicity and protective efficacy of these novel vaccine vectors in rhesus monkeys.

这个子项目是众多研究子项目之一